---
source_pdf: "https://drive.google.com/file/d/17jYawzuVUJnhNYe_syDj1kcHZO5TyAlm/view"
drive_folder: "Research"
type: research

ingested: 2025-12-28
original_filename: "ELV_ What We Heard Today.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/17jYawzuVUJnhNYe_syDj1kcHZO5TyAlm/view)

This report is intended for ek@virtuevc.com. Unauthorized distribution prohibited.

# nephron

## Elevance Health, Inc. (ELV)
### ELV: What We Heard Today

Elevance presented at a conference today and provided several updates, including details into current cost trends (i.e. Medicaid), non-recurring EPS items baked into 2025 guidance, and the intention to exit the standalone PDP business in 2026. In response to the commentary, we are updating our model to better reflect these items (more on this below). Notably, our full-year 2025 EPS estimate of $30.00 is unchanged but we are lowering our full-year 2026 EPS estimate to $30.50 representing growth of just 2%, but closer to 13% growth off run rate 2025 EPS (closer to $27 per share). We also provide a brief recap of some of the commentary that we found most notable:

1) To start, Elevance reiterated 2025 guidance (EPS and MLR) despite citing a softer Medicaid outlook than what was communicated in July. Consistent with prior commentary, the elevated Medicaid cost trend is driven ~1/3 by higher acuity of the population and ~2/3 by increased utilization and coding intensity. This includes higher usage in LTSS, behavioral health, and pharmacy. Operating margin performance will likely be softer than the outlook provided in July, as the company no longer expects sequential improvement in the back half of the year for Medicaid. Looking forward, the company mentioned that the range of potential 2026 outcomes for Medicaid is broader than it has been in the past. Elevance expects rates will continue to be misaligned from current cost trends in the near-term and noted the potential for early implementation of the budget reconciliation bill in some states in 2026. Offsetting softer Medicaid trends, cost trend in Individual ACA is developing favorably in 3Q, though costs continue to be elevated off historical levels. The primary causes of higher cost trend continue to be higher acuity from the shifting risk pool, increased utilization, and more aggressive provider coding tactics. The company is addressing higher costs in Individual ACA through disciplined pricing in 2026 and looks to return to a more normalized margin profile next year. Importantly, 3Q trends in Medicare and the Commercial Group business are both in line with prior expectations.

2) Elevance noted that there is approximately $3 per share of non-recurring favorable items currently included in 2025 EPS guidance. As a reminder, current 2025 EPS guidance is $30 per share for 2025. Based on today's commentary, it appears that the runrate EPS outlook for 2025 is closer to $27 per share. Elevance attributed the one-time favorable benefit primarily to tax, and VBC settlements that were mentioned last quarter, and favorability in net investment income that was not explicitly called out last quarter.

Based on this commentary we are updating our EPS estimates for 2026 but reiterating our full-year 2025 estimate of $30.00 per share. Our estimates now suggest that full year 2026 EPS will be $30.50, down from $32.00 previously. Our updated estimate calls for approximately 13% growth over the runrate 2025 EPS of approximately $27.00 per share.

CONTINUED...

Our price target of $336 is based on 11.0x our 2026 EPS of $30.50.

Please see important disclosures at the end of this report.

### SEPTEMBER 4, 2025

#### Managed Care & Providers
**Joshua Raskin**
646-876-0112
josh@nephronresearch.com

**Marco Criscuolo**
646-876-0114
marco@nephronresearch.com

**Jesse Coulter**
646-876-0113
jesse@nephronresearch.com

| Stock Rating          | Hold        |
| :-------------------- | :---------- |
| Price Target          | $336.00     |
| Price                 | $309.26     |
| Upside/Downside       | 9%          |
| 52-Week Range         | $273.71-$562.12 |
| Market Cap (bn)       | $72.4       |
| Enterprise Value (bn) | $90.2       |
| Dividend Yield        | 2.1%        |
| CF Yield              | 10.47%      |
| P/E (NTM)             | 9.9x        |
| EV/EBITDA (NTM)       | 8.5x        |
| Debt to Cap           | 41%         |

#### EPS
(FY DEC) | 1Q    | 2Q    | 3Q    | 4Q    | FY
:--------|:------|:------|:------|:------|:------
2024     | 10.64 | 10.12 | 8.37  | 3.84  | 32.98
P/E      |       |       |       |       | 9.4x
2025     | 11.97 | 8.84  | 4.75E | 4.43E | 30.00E
EPS Growth|      |       |       |       | (9.0)%
P/E      |       |       |       |       | 10.3x
2026     | 10.91E| 8.70E | 5.70E | 5.19E | 30.50E
Prior    | 11.83E| 9.35E | 5.66E | 5.15E | 32.00E
EPS Growth|      |       |       |       | 1.7%
P/E      |       |       |       |       | 10.1x

#### EPS Consensus
(FY DEC) | 1Q    | 2Q    | 3Q    | 4Q    | FY
:--------|:------|:------|:------|:------|:------
2024     | 10.64 | 10.12 | 8.37  | 3.84  | 32.98
2025     | 11.97 | 8.84  | 5.32E | 4.27E | 30.11E
Prior    | 11.97 | 8.84  | 5.31E | 4.28E | 30.11E
2026     | 11.87E| 9.29E | 6.51E | 4.04E | 31.96E
Prior    | 12.02E| 9.15E | 6.36E | 3.90E | 31.81E

This report is intended for ek@virtuevc.com. Unauthorized distribution prohibited.

# Nephron Research
### September 4, 2025

## Continued...

3) The company plans to exit their standalone Medicare Part D business in 2026 as well as certain MA markets/products. CFO Mark Kaye stated that this decision does not reflect underperformance but rather represents actions to focus the company's resources on where they can deliver the greatest impact. This is not terribly surprising in light of the modest contribution to overall results. Looking at our estimates, Elevance's standalone PDP revenue for 2026 is expected to be roughly $755 million (only ~0.4% of revenues) with a total membership of 220k lives. Assuming a 3% margin, this decision only amounts to a ~$23 million impact on earnings in 2026, or approximately $0.10 per share. As part of Elevance's review of their markets, the company will also exit some other plans and counties facing economic pressures in 2026. This decision will affect approximately another 150k MA members (not official guidance) across both individual and group businesses in 2026.

2

This report is intended for ek@virtuevc.com. Unauthorized distribution prohibited.

# Nephron Research
### September 4, 2025

## Important Disclosures, Disclaimers and Limitations of Liability

### Elevance Health, Inc. Price History, as of 09/03/2025

| Date    | Price (approx.) |
| :------ | :-------------- |
| Oct 22  | $450            |
| Jan 23  | $400            |
| Apr 23  | $440            |
| Jul 23  | $410            |
| Oct 23  | $390            |
| Jan 24  | $460            |
| Apr 24  | $510            |
| Jul 24  | $560            |
| Oct 24  | $470            |
| Jan 25  | $360            |
| Apr 25  | $390            |
| Jul 25  | $380            |

*Chart Y-axis range: $250 - $600*
*Note: Prices are approximate estimations from the line graph.*

**Certification.** The views expressed herein reflect the personal views of the research analyst(s) on the subject securities or issuers referred to. No part of any Nephron Research LLC ("Nephron") research analyst's compensation is or will be directly or indirectly related to the specific recommendations or views expressed.

This publication has been reviewed by Nephron in order to verify compliance with Nephron's internal policies on timeliness, against insider trading, disclosures regarding ratings systems, conflicts, and disciplinary matters.

As a categorical matter, Nephron Research has a policy of covering all issuers underwritten by NCMG LLC.

**No Advice or Solicitation.** Nephron is an independent research provider and is not a member of the FINRA or the SIPC and is not a registered broker-dealer or investment adviser. The reader acknowledges the following: (1) you are capable of making your own investment decisions and are not doing so in reliance of the content provided in this document; (2) neither Nephron or any individual author of this material is recommending or selling any securities to you; and (3) the content contained herein has not been tailored to any person's specific investment objectives and is not intended or provided as investment advice.

The information contained herein is not intended to be an inducement, invitation or commitment to purchase, provide or sell any securities, or to provide any recommendations on which individuals should rely for financial, securities, investment or other advice or to make any decision. Information herein is for informational purposes only and should not be construed by a potential subscriber as a solicitation to effect or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation. Nephron will not render specific investment advice to any individual or company and the content contained herein has not been tailored to the individual financial circumstances or objectives of any recipient. The securities and issuers discussed herein may not be suitable for the reader.

Nephron recommends that readers independently evaluate each issuer, security or instrument discussed herein and consult any independent advisors they believe necessary prior to making any investment decisions. Investment decisions should be made as part of an overall portfolio strategy and you should consult with professional financial, legal and tax advisors prior to making any investment decision.

**For Informational Purposes Only.** This publication is provided for information purposes only, is not comprehensive and has not been prepared for any other purpose. All information contained herein is provided "as is" for use at your own risk. The views and information in this publication are those of the author(s) and are subject to change without notice. Nephron has no obligation and assumes no responsibility to update its opinions or information in this publication. The information contained in this publication whether charts, articles, or any other statement or statements regarding market, stocks or other financial information has been obtained from sources that Nephron believes to be reliable, however Nephron does not represent, warrant or guarantee that it is accurate, complete or timely. Nothing herein should be interpreted to state or imply that past results are an indication of future performance.Rating System. Nephron uses an absolute rating system which rates the stocks of issuers as Buy, Sell, or Hold (see definitions below) backed by a 12 Month price target. Each analyst has a single price target on the stocks that they cover. The price target represents that analyst's expectation of where the stock will trade in the next 12 months. Upside/ downside scenarios, where provided, represent identified potential upside/potential downside to each analyst's price target over the same 12-month period. Buy - Current stock price generally represents upside to our 12-month price target of 20%+. Sell - Current stock price generally represents downside to our 12-month price target of 20%+. Hold - Current stock generally represents limited opportunities on both the long and short side over 12-month period.

The entire contents of this publication should be carefully read, including the definitions of all ratings. No inferences of its contents should be drawn from the ratings alone.

**Disclaimer Regarding Forward Looking Statements.** The information herein may include forward looking statements which are based on our current opinions, expectations and projections.

All ratings and price targets are subject to the realization of the assumptions on which analyst(s) based their views. The assumptions are subject to significant uncertainties and contingencies which may change materially in response to small changes in one or more of the assumptions. No representation or warranty is made as to the reasonableness of the assumptions that contributed to the rating or target price or as to any other financial information contained herein. Nephron undertakes no obligation to update or revise any forward looking statements. Actual results could differ materially from those anticipated in any forward looking statements. Nothing herein should be interpreted to state or imply that past results or events are an indication of future performance.

**IRS Circular 230 Prepared Materials Disclaimer.** Nephron does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-

3

This report is intended for ek@virtuevc.com. Unauthorized distribution prohibited.

# Nephron Research
### September 4, 2025

related obligations or penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

**No Warranties.** Nephron disclaims to the fullest extent permitted by law any warranties and representations of any kind, whether express or implied, including, without limitation, warranties of merchantability or fitness, for any purpose and accuracy or for any other warranty which may otherwise be applicable or created by operation of law, custom, trade usage or course of dealings. Nephron makes no representation that (i) the content will meet your requirements, (ii) the content will be uninterrupted, timely, secure, or error free, or (iii) the information that may be obtained from the use of the content (including any information and materials herein) will be compliant, correct, complete, accurate or reliable. THERE ARE NO WARRANTIES EXPRESSED OR IMPLIED, AS TO ACCURACY, COMPLETENESS, OR RESULTS OBTAINED FROM ANY INFORMATION.

**Disclaimer of Liability.** We shall not accept any liability with respect to the accuracy or completeness of any information herein, or omitted to be included herein, or any information provided, or omitted to be provided, by any third party. We shall not be liable for any errors or inaccuracies, regardless of cause, or the lack of timeliness, or for any delay, error or interruption in the transmission thereof to the user. TO THE FULLEST EXTENT PERMITTED BY LAW IN YOUR JURISDICTION, IN NO EVENT SHALL NEPHRON BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL PUNITIVE, SPECIAL OR INCIDENTAL OR OTHER DAMAGES ARISING OUT OF THE CONTENT.

**Reproduction and Distribution Strictly Prohibited.** Â© Copyright Nephron Research LLC. No part of this publication or its contents may be downloaded, stored in a retrieval system, further transmitted, or otherwise reproduced or redistributed in any manner without the prior written permission of Nephron. The contents herein are directed at, and produced for the exclusive use of Nephron clients and intended recipients. No license is granted to Nephron clients and/ or the intended recipient Nephron will not treat unauthorized recipients of this publication as its clients.

4